Department of Surgery, Division of Hepatobiliary & Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310000, China.
Department of Hepatopancreatobiliary Surgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Research Center of Diagnosis & Treatment Technology for Hepatocellular Carcinoma of Zhejiang Province, Hangzhou, 310000, China.
Future Oncol. 2022 Jun;18(19):2401-2413. doi: 10.2217/fon-2021-1608. Epub 2022 May 3.
To investigate the prognostic value of DNA methylation of tumor suppressor genes for hepatocellular carcinoma (HCC) recurrence after liver transplantation. gene was selected according to The Cancer Genome Atlas dataset. Tumor tissues and clinical data of 85 HCC patients who received a liver transplantation were retrospectively enrolled and next-generation methylation sequencing was performed. Risk factors were determined using the Cox proportional-hazard-regression model. The methylation site (chromosome 5, position 112043544) was an independent predictor of post-transplant HCC recurrence. Patients with hyper-methylated 112043544 experienced superior recurrence-free survival (p = 0.021) and had a decreased proportion of microvascular invasion (p = 0.017). 112043544 also predicted recurrence risk in patients beyond selection criteria. 112043544 methylation may serve as a potential biomarker for post-transplant HCC recurrence.
探讨肿瘤抑制基因 DNA 甲基化对肝癌（HCC）肝移植后复发的预后价值。根据 The Cancer Genome Atlas 数据集选择了 基因。回顾性纳入 85 例接受肝移植的 HCC 患者的肿瘤组织和临床资料，并进行下一代甲基化测序。使用 Cox 比例风险回归模型确定危险因素。甲基化位点（染色体 5，位置 112043544）是移植后 HCC 复发的独立预测因子。112043544 高甲基化的患者具有更好的无复发生存率（p=0.021），微血管侵犯的比例降低（p=0.017）。112043544 也可预测超出选择标准的患者的复发风险。112043544 甲基化可能是移植后 HCC 复发的潜在生物标志物。
